The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Metronomic capecitabine as second-line treatment for patients with hepatocellular carcinoma with preserved liver function: A phase II study.
F. de Rosa
No relevant relationships to disclose
V. Agostini
No relevant relationships to disclose
S. Di Girolamo
No relevant relationships to disclose
P. Andreone
No relevant relationships to disclose
F. Trevisani
No relevant relationships to disclose
L. Bolondi
No relevant relationships to disclose
A. D. Pinna
No relevant relationships to disclose
C. Serra
No relevant relationships to disclose
R. Golfieri
No relevant relationships to disclose
G. Biasco
No relevant relationships to disclose
G. Brandi
No relevant relationships to disclose